Constructs of biotin mimetic peptide with CC49 single-chain Fv designed for tumor pretargeting

Peptides

Volumn 24, Issue 3, 2003, Pages 353-362

  Pavlinkova, Gabriela ^a   Batra, Surinder K ^b   Colcher, David ^c   Booth, Barbara J M ^a   Baranowska Kortylewicz, Janina ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b NEBRASKA MEDICAL CENTER   (United States)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Biotin mimetic peptide; Pretargeting radiotherapy; Single chain antibody fragments; Streptavidin

Indexed keywords

BIOTIN MIMETIC PEPTIDE; BIOTIN MIMETIC PEPTIDE SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY STREPTAVIDIN COMPLEX I 125; DIMER; IODINE 125; MONOCLONAL ANTIBODY CC49; MONOMER; PEPTIDE; RADIOPHARMACEUTICAL AGENT; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; STREPTAVIDIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY ENGINEERING; ANTIBODY SPECIFICITY; ANTIGEN RECOGNITION; ARTICLE; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CARBOXY TERMINAL SEQUENCE; COMPLEX FORMATION; CONTROLLED STUDY; DRUG PROTEIN BINDING; DRUG TARGETING; FEMALE; IN VITRO STUDY; ISOTOPE LABELING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN STRUCTURE; PROTEIN TARGETING; RADIOIMMUNOTHERAPY; XENOGRAFT;

EID: 0038404834     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0196-9781(03)00049-4     Document Type: Article

References (51)

1. Adams G.P., Schier R., Marshall K., Wolf E.J., McCall A.M., Marks J.D.et al. Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies. Cancer Res. 58:1998;485-490.
2. Axworthy D.B., Reno J.M., Hylarides M.D., Mallett R.W., Theodore L.J., Gustavson L.M.et al. Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc. Natl. Acad. Sci. U.S.A. 97:2000;1802-1807.
3. Barbet J., Kraeber-Bodere F., Vuillez J.P., Gautherot E., Rouvier E., Chatal J.F. Pretargeting with the affinity enhancement system for radioimmunotherapy. Cancer Biother. Radiopharm. 14:1999;153-166.
4. Beresford G.W., Pavlinkova G., Booth B.J., Batra S.K., Colcher D. Binding characteristics and tumor targeting of a covalently linked divalent CC49 single-chain antibody. Int. J. Cancer. 81:1999;911-917.
5. Bird R.E., Hardman K.D., Jacobson J.W., Johnson S., Kaufman B.M., Lee S.M.et al. Single-chain antigen-binding proteins. Science. 242:1988;423-426.
6. Breitz H.B., Weiden P.L., Beaumier P.L., Axworthy D.B., Seiler C., Su F.M.et al. Clinical optimization of pretargeted radioimmunotherapy with antibody-streptavidin conjugate and 90Y-DOTA-biotin. J. Nucl. Med. 41:2000;131-140.
7. Casey J.L., Napier M.P., King D.J., Pedley R.B., Chaplin L.C., Weir N.et al. Tumor targeting of humanised cross-linked divalent-Fab′ antibody fragments: a clinical phase I/II study. Br. J. Cancer. 86:2002;1401-1410.
8. Colcher D., Zalutsky M., Kaplan W., Kufe D., Austin F., Schlom J. Radiolocalization of human mammary tumors in athymic mice by a monoclonal antibody. Cancer Res. 43:1983;736-742.
9. Cremonesi M., Ferrari M., Chinol M., Stabin M.G., Grana C., Prisco G.et al. Three-step radioimmunotherapy with yttrium-90 biotin: dosimetry and pharmacokinetics in cancer patients. Eur. J. Nucl. Med. 26:1999;110-120.
10. Domingo R.J., Reilly R.M. Pre-targeted radioimmunotherapy of human colon cancer xenografts in athymic mice using streptavidin-CC49 monoclonal antibody and 90Y-DOTA-biotin. Nucl. Med. Commun. 21:2000;89-96.
11. Dosio F., Magnani P., Paganelli G., Samuel A., Chiesa G., Fazio F. Three-step tumor pre-targeting in lung cancer immunoscintigraphy. J. Nucl. Biol. Med. 37:1993;228-232.
12. Goel A., Colcher D., Baranowska-Kortylewicz J., Augustine S., Booth B.J., Pavlinkova G.et al. Genetically engineered tetravalent single-chain Fv of the pancarcinoma monoclonal antibody CC49: improved biodistribution and potential for therapeutic application. Cancer Res. 60:2000;6964-6971.
13. Goldenberg D.M. Targeted therapy of cancer with radiolabeled antibodies. J. Nucl. Med. 43:2002;693-713.
14. Goodwin D.A., Meares C.F. Pretargeting: general principles. Cancer. 80:1997;2675-2680.
15. Grana C., Chinol M., Robertson C., Mazzetta C., Bartolomei M., De Cicco C.et al. Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: a pilot study. Br. J. Cancer. 86:2002;207-212.
16. Gregory K.J., Bachas L.G. Use of a biomimetic peptide in the design of a competitive binding assay for biotin and biotin analogues. Anal. Biochem. 289:2001;82-88.
17. Karacay H., Sharkey R.M., McBride W.J., Griffiths G.L., Qu Z., Chang K.et al. Pretargeting for cancer radioimmunotherapy with bispecific antibodies: role of the bispecific antibody's valency for the tumor target antigen. Bioconjug. Chem. 13:2002;1054-1070.
18. Kassis A.I., Jones P.L., Matalka K.Z., Adelstein S.J. Antibody-dependent signal amplification in tumor xenografts after pretreatment with biotinylated monoclonal antibody and avidin or streptavidin. J. Nucl. Med. 37:1996;343-352.
19. Knox S.J., Goris M.L., Tempero M., Weiden P.L., Gentner L., Breitz H.et al. Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. Clin. Cancer Res. 6:2000;406-414.
20. Kobayashi H., Sakahara H., Endo K., Hosono M., Yao Z.S., Toyama S.et al. Comparison of the chase effects of avidin, streptavidin, neutravidin, and avidin-ferritin on a radiolabeled biotinylated anti-tumor monoclonal antibody. Jpn. J. Cancer Res. 86:1995;310-314.
21. Kobayashi H., Sakahara H., Endo K., Yao Z.S., Toyama S., Konishi J. Repeating the avidin "chase" markedly improved the biodistribution of radiolabelled biotinylated antibodies and promoted the excretion of additional background radioactivity. Eur. J. Cancer. 31A:1995;1689-1696.
22. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227:1970;680-685.
23. Leichner P.K., Akabani G., Colcher D., Harrison K.A., Hawkins W.G., Eckblade M.et al. Patient-specific dosimetry of indium-111- and yttrium-90-labeled monoclonal antibody CC49. J. Nucl. Med. 38:1997;512-516.
24. Lowry O.H., Rosenbrough N.J., Farr A.L., Randall R.J. Protein measurement with Folin phenol. J. Biol. Chem. 193:1951;265-275.
25. Lyubsky S., Madariaga J., Lozowski M., Mishriki Y., Schuss A., Chao S.et al. A tumor-associated antigen in carcinoma of the pancreas defined by monoclonal antibody B72.3. Am. J. Clin. Pathol. 89:1988;160-167.
26. Magnani P., Paganelli G., Modorati G., Zito F., Songini C., Sudati F.et al. Quantitative comparison of direct antibody labeling and tumor pretargeting in uveal melanoma. J. Nucl. Med. 37:1996;967-971.
27. Marshall D., Pedley R.B., Boden J.A., Boden R., Melton R.G., Begent R.H. Polyethylene glycol modification of a galactosylated streptavidin clearing agent: effects on immunogenicity and clearance of a biotinylated anti-tumor antibody. Br. J. Cancer. 73:1996;565-572.
28. Mayer A., Tsiompanou E., O'Malley D., Boxer G.M., Bhatia J., Flynn A.A.et al. Radioimmunoguided surgery in colorectal cancer using a genetically engineered anti-CEA single-chain Fv antibody. Clin. Cancer Res. 6:2000;1711-1719.
29. Meredith R.F., Khazaeli M.B., Macey D.J., Grizzle W.E., Mayo M., Schlom J.et al. Phase II study of interferon-enhanced 131I-labeled high affinity CC49 monoclonal antibody therapy in patients with metastatic prostate cancer. Clin. Cancer Res. 5:1999;3254s-3258s.
30. Milenic D.E., Yokota T., Filpula D.R., Finkelman M.A., Dodd S.W., Wood J.F.et al. Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49. Cancer Res. 51:1991;6363-6371.
31. Paganelli G., Orecchia R., Jereczek-Fossa B., Grana C., Cremonesi M., De Braud F.et al. Combined treatment of advanced oropharyngeal cancer with external radiotherapy and three-step radioimmunotherapy. Eur. J. Nucl. Med. 25:1998;1336-1339.
32. Pantoliano M.W., Bird R.E., Johnson S., Asel E.D., Dodd S.W., Wood J.F.et al. Conformational stability, folding, and ligand-binding affinity of single-chain Fv immunoglobulin fragments expressed in Escherichia coli. Biochemistry. 30:1991;10117-10125.
33. Pavlinkova G., Beresford G.W., Booth B.J., Batra S.K., Colcher D. Pharmacokinetics and biodistribution of engineered single-chain antibody constructs of MAb CC49 in colon carcinoma xenografts. J. Nucl. Med. 40:1999;1536-1546.
34. Press O.W., Corcoran M., Subbiah K., Hamlin D.K., Wilbur D.S., Johnson T.et al. A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts. Blood. 98:2001;2535-2543.
35. Rixon M.W., Gourlie B.B., Kaplan D.A., Schlom J., Mezes P.S. Preferential use of a H chain V region in antitumor-associated glycoprotein-72 monoclonal antibodies. J. Immunol. 151:1993;6559-6568.
36. Rucker R., Bresler H.S., Heffelfinger M., Kim J.A., Martin E.W.J., Triozzi P.L. Low-dose monoclonal antibody CC49 administered sequentially with granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal cancer. J. Immunother. 22:1999;80-84.
37. Schmidt T.G., Koepke J., Frank R., Skerra A. Molecular interaction between the Strep-tag affinity peptide and its cognate target, streptavidin. J. Mol. Biol. 255:1996;753-766.
38. Schmidt T.G., Skerra A. The random peptide library-assisted engineering of a C-terminal affinity peptide, useful for the detection and purification of a functional Ig Fv fragment. Protein Eng. 6:1993;109-122.
39. Schmidt T.G., Skerra A. One-step affinity purification of bacterially produced proteins by means of the "Strep tag" and immobilized recombinant core streptavidin. J. Chromatogr. A. 676:1994;337-345.
40. Schultz J., Lin Y., Sanderson J., Zuo Y., Stone D., Mallett R.et al. A tetravalent single-chain antibody-streptavidin fusion protein for pretargeted lymphoma therapy. Cancer Res. 60:2000;6663-6669.
41. Tempero M., Leichner P., Baranowska-Kortylewicz J., Harrison K., Augustine S., Schlom J.et al. High-dose therapy with 90Yttrium-labeled monoclonal antibody CC49: a phase I trial. Clin. Cancer Res. 6:2000;3095-3102.
42. Tempero M., Leichner P., Dalrymple G., Harrison K., Augustine S., Schlam J.et al. High-dose therapy with iodine-131-labeled monoclonal antibody CC49 in patients with gastrointestinal cancers: a phase I trial. J. Clin. Oncol. 15:1997;1518-1528.
43. Thor A., Ohuchi N., Szpak C.A., Johnston W.W., Schlom J. Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3. Cancer Res. 46:1986;3118-3124.
44. Vesely D.L., Kemp S.F., Elders M.J. Isolation of a biotin receptor from hepatic plasma membranes. Biochem. Biophys. Res. Commun. 143:1987;913-916.
45. Voss S., Skerra A. Mutagenesis of a flexible loop in streptavidin leads to higher affinity for the Strep-tag II peptide and improved performance in recombinant protein purification. Protein Eng. 10:1997;975-982.
46. Wilbur D.S., Hamlin D.K., Vessella R.L., Stray J.E., Buhler K.R., Stayton P.S.et al. Antibody fragments in tumor pretargeting. Evaluation of biotinylated Fab′ colocalization with recombinant streptavidin and avidin. Bioconjug. Chem. 7:1996;689-702.
47. Wilbur D.S., Stayton P.S., To R., Buhler K.R., Klumb L.A., Hamlin D.K.et al. Streptavidin in antibody pretargeting. Comparison of a recombinant streptavidin with two streptavidin mutant proteins and two commercially available streptavidin proteins. Bioconjug. Chem. 9:1998;100-107.
48. Wu A.M., Chen W., Raubitschek A., Williams L.E., Neumaier M., Fischer R.et al. Tumor localization of anti-CEA single-chain Fvs: improved targeting by non-covalent dimers. Immunotechnology. 2:1996;21-36.
49. Yao Z., Zhang M., Axworthy D.B., Wong K.J., Garmestani K., Park L.et al. Radioimmunotherapy of A431 xenografted mice with pretargeted B3 antibody-streptavidin and (90)Y-labeled 1,4,7,10-tetraazacyclododecane-N,N′,N″,N″′- tetraacetic acid (DOTA)-biotin. Cancer Res. 62:2002;5755-5760.
50. Yao Z., Zhang M., Kobayashi H., Sakahara H., Nakada H., Yamashina I.et al. Improved targeting of radiolabeled streptavidin in tumors pretargeted with biotinylated monoclonal antibodies through an avidin chase. J. Nucl. Med. 36:1995;837-841.
51. Yao Z., Zhang M., Sakahara H., Saga T., Kobayashi H., Nakamoto Y.et al. Increased streptavidin uptake in tumors pretargeted with biotinylated antibody using a conjugate of streptavidin-fab fragment. Nucl. Med. Biol. 25:1998;557-560.